CN1227023C - Drug for treating coronary heart disease, angina and preparation method - Google Patents
Drug for treating coronary heart disease, angina and preparation method Download PDFInfo
- Publication number
- CN1227023C CN1227023C CN 200310105455 CN200310105455A CN1227023C CN 1227023 C CN1227023 C CN 1227023C CN 200310105455 CN200310105455 CN 200310105455 CN 200310105455 A CN200310105455 A CN 200310105455A CN 1227023 C CN1227023 C CN 1227023C
- Authority
- CN
- China
- Prior art keywords
- medicine
- weight portions
- angina pectoris
- moschus
- heart disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 title claims abstract description 57
- 206010002383 Angina Pectoris Diseases 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 208000029078 coronary artery disease Diseases 0.000 title claims abstract description 10
- 229940079593 drug Drugs 0.000 title description 20
- 239000000843 powder Substances 0.000 claims abstract description 24
- 241000218176 Corydalis Species 0.000 claims abstract description 17
- 238000001035 drying Methods 0.000 claims abstract description 12
- 235000002789 Panax ginseng Nutrition 0.000 claims abstract description 4
- 239000000284 extract Substances 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 26
- 244000153234 Hibiscus abelmoschus Species 0.000 claims description 25
- 235000015511 Liquidambar orientalis Nutrition 0.000 claims description 18
- 239000004870 Styrax Substances 0.000 claims description 18
- 235000000126 Styrax benzoin Nutrition 0.000 claims description 18
- 241000208340 Araliaceae Species 0.000 claims description 14
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 14
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 14
- 235000008434 ginseng Nutrition 0.000 claims description 14
- 239000012141 concentrate Substances 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 11
- 239000006187 pill Substances 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 239000008361 herbal raw material Substances 0.000 claims description 4
- 244000028419 Styrax benzoin Species 0.000 claims 2
- 241000411851 herbal medicine Species 0.000 abstract description 6
- 241000402754 Erythranthe moschata Species 0.000 abstract 2
- 241001060310 Styracaceae Species 0.000 abstract 2
- 235000001361 Styrax officinalis Nutrition 0.000 abstract 2
- 235000019382 gum benzoic Nutrition 0.000 abstract 2
- 238000005538 encapsulation Methods 0.000 abstract 1
- 239000000469 ethanolic extract Substances 0.000 abstract 1
- 235000015097 nutrients Nutrition 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 description 23
- 230000036407 pain Effects 0.000 description 23
- 230000000694 effects Effects 0.000 description 22
- 241000736148 Styrax Species 0.000 description 16
- 208000024891 symptom Diseases 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 10
- 238000002481 ethanol extraction Methods 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 210000000038 chest Anatomy 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 7
- 239000000006 Nitroglycerin Substances 0.000 description 7
- 230000003203 everyday effect Effects 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 235000019634 flavors Nutrition 0.000 description 7
- 229960003711 glyceryl trinitrate Drugs 0.000 description 7
- 230000010354 integration Effects 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 206010008479 Chest Pain Diseases 0.000 description 6
- 230000003442 weekly effect Effects 0.000 description 6
- 206010062717 Increased upper airway secretion Diseases 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 230000002354 daily effect Effects 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 208000026435 phlegm Diseases 0.000 description 5
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 4
- 208000035286 Spontaneous Remission Diseases 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 230000000302 ischemic effect Effects 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- 230000002085 persistent effect Effects 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 210000000115 thoracic cavity Anatomy 0.000 description 3
- 230000002861 ventricular Effects 0.000 description 3
- 206010014080 Ecchymosis Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229930194542 Keto Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000003255 drug test Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 230000003118 histopathologic effect Effects 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 230000036284 oxygen consumption Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000013077 scoring method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 235000016936 Dendrocalamus strictus Nutrition 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 241000201295 Euphrasia Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021079 Hypopnoea Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 208000000501 Lipidoses Diseases 0.000 description 1
- 206010024585 Lipidosis Diseases 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010041591 Spinal osteoarthritis Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 208000036319 cervical spondylosis Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008899 fufang danshen Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 208000005801 spondylosis Diseases 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- KWEUUBDPVVHQAL-MSQVLRTGSA-K trisodium;[[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl] phosphate Chemical compound [Na+].[Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O KWEUUBDPVVHQAL-MSQVLRTGSA-K 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention provides medicine for treating coronary disease and angina pectoris, and a preparation method for the medicine. The medicine is prepared from raw materials of Chinese herbal medicine such as 0.01 to 40 weight portions of musk, 9 to 600 weight portions of corydalis tuber, 0.01 to 30 weight portions of storax and 6 to 400 weight portions of red ginseng. The medicine extracts the effective nutrient components of the corydalis tuber and the red ginseng by ethanol extract. Fine powder is then formed by concentrating and drying. The fine powder is then evenly ground with the musk and the storax. The oral administration preparation is processed, and the present invention is formed by encapsulation.
Description
Technical field:
The present invention relates to a kind of treatment treating coronary heart disease and angina pectoris, especially a kind of oral agents with herbal raw material preparation the invention still further relates to the preparation method of this medicine.
Background technology:
Angina pectoris is lipidosiss such as coronary endometrium cholesterol, form atheromatous plaque to the lumen of vessels internal projection, and with fibrosis and calcification, cause coronary atherosclerosis, narrow even entirely shut, the traditional Chinese medical science thinks that this disease belongs to " thoracic obstruction ", " pained " category is by qi depression to blood stasis, blood-vessel obstructive and cause stagnation of QI and blood may bring about pain, six climate exopathogens cold-evil invades, so that cold coagulation is in arteries and veins, the contracture spasm, and diet is careless, rich and fatty diet, become and give birth to phlegm-damp, phlegm-damp is invaded, and occupies peaceful and spacious district, or the bright network of expectorant heat, scorching on the bad temper, or qi-blood-body fluid negative and positive deficiency, so that void and blood is capable slowly causes a disease.The Chinese medicine of existing treatment angina pectoris intentionally can relax, heart nourishing, Fel Ursi pills for curing heart disease, FUFANG DANSHEN DIWAN etc., but these medicines are big by the flavour of a drug amount of composition mostly, active component is clear and definite inadequately, dose is big, onset waits shortcoming slowly, and is not satisfactory to the therapeutic effect of qi stagnation and blood stasis type angina pectoris.
Summary of the invention:
One of purpose of the present invention provides that a kind of flavour of a drug composition amount is little, and active component is clear and definite, and dose is little, and is rapid-action, thereby it is better to reach curative effect, and is with low cost, can play better treatment and medicine without any side effects to angina pectoris; It is simple that two of purpose provides a kind of technology that one of achieves the goal, the preparation method of this medicine of easy operating.
One of purpose of the present invention can realize by following technical measures:
The present invention is the medicament made from the herbal raw material of following weight parts proportioning:
Moschus 0.1～5, Rhizoma Corydalis 9～20, Styrax 0.3～10, Radix Ginseng Rubra 6.
Rhizoma Corydalis of the present invention can substitute with Rhizoma Chuanxiong, and when the Rhizoma Chuanxiong addition was 9～200 weight portions, the addition of Radix Ginseng Rubra was 6～400, Moschus is 0.1～40, Styrax is 0.3～30 weight portion.
Radix Ginseng Rubra of the present invention can substitute with Radix Ginseng.
Moschus (Moschus) nature and flavor suffering, temperature, GUIXIN, spleen channel.The refreshment of having one's ideas straightened out, blood circulation promoting and dispersing pathogen accumulation, pain relieving is used for trusted subordinate's sudden pain, arthralgia pain." property of medicine opinion " cloud " except that pained ... tranquilizing mind "." book on Chinese herbal medicine is stated " cloud " usefulness of Moschus, it will can lead to all keys one language, cover all diseases in for stop up, for knot, be the person of closing, when blaming it to treat it.So do not open its heap soil or fertilizer over and around the roots, its knot that looses, logical its closes, then where set about? "
Rhizoma Corydalis (Rhizoma Corydalis) nature and flavor suffering, hardship, temperature.Return liver, spleen channel.Invigorate blood circulation, promoting the circulation of QI, pain relieving.Be used for the breast side of body, epigastric pain, the amenorrhea dysmenorrhea.But the principal drug assistance aromatic herbs activating YANG is open to the custom and is had one's ideas straightened out, promoting flow of QI and blood, blood-activating analgetic, walk to scurry sensible, through sick institute.
Styrax (Styrax) nature and flavor suffering, temperature, GUIXIN, spleen channel.Be used for the apoplexy syncope due to accumulation of phlegm, breast abdomen cold type of pain, warm disease." Styrax, the gas of poly-all perfume (or spice) forms " book on Chinese herbal medicine meets former " cloud, and is can saturating all keys dirty, wards off all not just gas." " book on Chinese herbal medicine is looked for the truth " cloud " lose consciousness, and the clouds and mists in the mountains miasma is wet, attacks in meridians, fills in all key persons, and non-this does not remove by accumulation of phlegm." " book on Chinese herbal medicine just " calls it can " end QI rising in reverse order pain ".
Sweet, the little hardship of Radix Ginseng Rubra (Radix Ginseng Rubra) nature and flavor, temperature.Go into spleen, lung meridian.Strongly invigorating primordial QI is arranged, beneficial heart and tranquilizing mind, the merit of promoting the production of body fluid and taking off admittedly.The Shennong's Herbal meaning " main tonifying five ZANG-organs, peace spirit is decided soul, and spasmolytic is throbbed with fear, and removes pathogen, makes eye bright, happy Fructus Alpiniae Oxyphyllae." QI invigorating used nourishes heart, turn round and look at and protect it.Qi being the governor of blood, the motive is abundant, passes unimpeded to promote painstaking effort.Radix Ginseng Rubra can help monarch-minister drug with eliminating evil simultaneously.
Rhizoma Chuanxiong (Rhizoma Chuanxiong) nature and flavor suffering, temperature are returned liver, gallbladder, pericardium channel.Kind blood-activating and qi-promoting, promoting blood circulation, pain relieves the pain." all families of solar corona book on Chinese herbal medicine " carries: and " control a wind cutting, all gas, all strains, all blood are mended five kinds of over strain, and strengthening bone and muscle is transferred many arteries and veins, broken crux stagnated blood ... "." Mingyi Bielu " calls it can dispel " all cold gas, the hard pain of trusted subordinate.”
Moschus is the monarch drug promoting blood circulation to restore menstrual flow.Rhizoma Corydalis is a ministerial drug, and the principal drug assistance aromatic herbs activating YANG is open to the custom and is had one's ideas straightened out, promoting flow of QI and blood, blood-activating analgetic, walk to scurry sensible, through sick institute.Styrax is an adjuvant drug, sensible numbness, the eliminating phlegm relieving accumulation of pathogens opened of principal drug assistance.Radix Ginseng Rubra is a messenger drug, helps monarch-minister drug with eliminating evil.
Said medicament is a said oral agents on any pharmaceutics, and said oral agents is tablet, capsule, drop pill, watered pill, granule.
Moschus in the herbal raw material of the present invention can replace with the artificial Moschus.
Two of purpose of the present invention can realize by following technical measures:
The preparation method of medicine of the present invention:
A, the Rhizoma Corydalis of 9～20 weight portions and the red ginseng powder of 6 weight portions are broken into coarser powder, add 4～10 times of amount 40～80% ethanol, extract twice, collect extracting solution, reclaim ethanol,, make fine powder again through concentrate drying;
B, with fine powder and the Moschus of 0.1～5 weight portion, the Styrax of 0.3～10 weight portion of a operation preparation, grind mixing altogether, be processed into oral agents, encapsulate.
Extraction in the preparation method of medicine of the present invention comprises extracting method all in the pharmaceutical book, as backflow, extraction, percolation etc.
One, pharmacodynamic study:
Medicine of the present invention has obvious antagonism to ADP sodium salt and collagen-induced platelet aggregation, can significantly reduce the platelet maximum agglutination rate; The acute myocardial ischemia that the domesticated dog coronary ligation is caused has tangible antagonism, can significantly reduce epicardial electrogram ∑-ST and myocardium N-BT dyeing district; Medicine duodenal administration of the present invention can obviously reduce anesthetized dog systolic pressure (SBP), diastolic pressure (DBP) and heart rate (HR), can obviously reduce simultaneously left ventricular pressure and maximum rate of change thereof (LVP, LVP ± dp/dtmax), left ventricular work and cardiac muscular tension time index are also had reduction effect significantly; Can obviously suppress the formation of rat arteriovenous shut thrombosis, each index tool of hemorheology of rat is had some improvement.Show that medicine of the present invention can be by reducing cardiac afterload, reducing myocardial contractility and myocardial oxygen consumption index (ventricular stroke work and cardiac muscular tension time index); reduce myocardial oxygen consumption; improve the myocardial ischemia equilibrium of supply and demand; ischemic myocardium is produced protective effect, reduce infarction size, can pass through antiplatelet aggregative activity simultaneously; blood viscosity lowering; improve blood circulation, prevention thrombosis plays a role in the angina pectoris treatment.
Two, studies on acute toxicity:
Maximum tolerated dose is greater than 50.4g/kg in the medicine mouse stomach of the present invention administration one day.It is 2 slices/time that medicine of the present invention is intended clinical consumption, 3 times/day, every contains medicine 0.305g of the present invention, in adult's average weight 60kg, average dosage is about 0.05g/kg, and therefore this medicine maximum tolerated dose is about 1000 times with dosage of the clinical day for human beings in prediction on such basis.
Three, long term toxicity research:
1, medicine 0.5g/kg/dig of the present invention is following is 3 months safe dose of rat.The every index impermanence of animal general behavior, body weight gain, routine urianlysis, routine blood test, serum biochemistry and histopathologic examination.
2, the 5.0g/kg/dig rat is 3 months, every indexs such as animal general behavior, routine urianlysis, routine blood test, serum biochemistry and histopathologic examination are not all found the ANOMALOUS VARIATIONS relevant with medicine of the present invention, body weight gain slows down in only visible 6 weeks of administration, and 6 all backs are basic recovers normal.This is tested used high and low dose and has reached 100 times and 10 times that intend clinical medicine dose, shows that thus clinical drug medication of the present invention is safe.
The clinical observation of medicine qi stagnation and blood stasis type coronary heart disease of the present invention:
(1) case choice criteria:
1, diagnostic criteria: formulate with reference to " the clinical research guideline of the new Chinese medicine test thoracic obstruction (angina pectoris) ".
(1) thoracic obstruction tcm diagnosis standard:
1. suffocating pain over the chest, even chest pain radiating to the back;
2. the lighter only feel uncomfortable in chest, feel suffocated, hypopnea;
3. Electrocardioscopy has the ischemic change or the exercise test positive.
(2) Chinese medical discrimination and syndrome criterion:
Syndrome of qi stagnation and blood stasis:
Main symptom: uncomfortable in chest, chest pain.
Inferior disease: cardiopalmus, breathe hard, feel suffocated two side of body distending pains.
Picture of the tongue, pulse condition: dark tongue quality, or purple is dark or ecchymosis is arranged, white and thin fur, stringy and hesitant pulse.
Above primary symptom indispensability, inferior disease have concurrently more than 1, and be in conjunction with picture of the tongue, pulse condition, promptly diagnosable.
(3) Western medicine diagnose standard:
Formulate with reference to International Society of Cardiology and World Health Organization's clinical name standardization associating special topic group report " name of ischemic heart desease and diagnostic criteria ".
The fatigue angina pectoris: the anginal feature of fatigue is that behind rest or the buccal nitroglycerin, pain often can rapidly disappear because the of short duration chest pain of being brought out under the situation of motion or other increase myocardium requirementing keto quantities is shown effect.Can be divided three classes: a. hair style fatigue angina pectoris just: the course of disease is in one month.B. stable type fatigue angina pectoris: the course of disease was stabilized in more than one month.C. deterioration type fatigue angina pectoris: number of times, the order of severity and persistent period that the equal extent fatigue is brought out increase the weight of suddenly.
Spontaneous angina pectoris: the feature of spontaneous angina pectoris is that the chest pain outbreak does not have obvious relation with the increase of myocardium requirementing keto quantity.Compare with the fatigue angina pectoris, this pain general persistence is longer, and degree is heavier, and does not alleviate for nitroglycerin.This type is not seen enzymic change, and electrocardiogram often occurs that some temporary ST section is forced down or the T ripple changes.Spontaneous angina pectoris can take place separately or merge existence with the fatigue angina pectoris.
2, obstruction of qi in the chest and cardialgia weight grade scale:
Formulate with reference to the combination of Chinese and Western medicine in 1979 test angina pectoris and arrhythmia forum " angina pectoris and ECG curative effect evaluation criteria ".
(1) slight: as have than the classical angina outbreak, continue several minutes at every turn, show effect 2-3 time at least weekly, or show effect 1-3 time every day, but pain to be not heavy, need obey nitroglycerin sometimes.Angina pectoris symptom integration≤8 minute.
(2) moderate: have every day repeatedly than the classical angina outbreak, each persistent period number is minute heavier to 10 minutes pain, generally needs the buccal nitroglycerin.Angina pectoris symptom integration 9-16 branch.
(3) than severe: classical angina outbreak is for several times arranged every day, thereby influence activities of daily living (for example defecate, wear the clothes etc.), the persistent period of at every turn showing effect is longer, and need are the buccal nitroglycerin repeatedly.Angina pectoris symptom integration 〉=17 minute.
(4) severe: this type of patient's pain attack times and degree all compare severe and attach most importance to, and do not classify this medicine observation program as.
3, angina pectoris symptom scoring method:
(1) attack times:
0 minute: do not have.
2 minutes: show effect 2-6 time weekly.
4 minutes: showed effect 1-3 every day.
6 minutes: show effect every day more than 4 times.
(2) persistent period:
0 minute: do not have.
2 minutes: each pain continued≤5 minutes.
4 minutes: each pain continued＞5＜10 minutes.
6 minutes: each pain continued 〉=10 minutes.
(3) pain degree:
0 minute: do not have.
2 minutes: do not influence daily life through the alleviation of having a rest during outbreak.
4 minutes: need drug test during outbreak, can continue normal activity after the alleviation.
6 minutes: outbreak was frequent, influences activities of daily living (but as the induced symptom of wearing the clothes, take food, take a walk, defecate).
(4) nitroglycerin consumption:
0 minute: do not have
2 minutes: obey the 1-4 sheet weekly.
4 minutes: obey the 5-9 sheet weekly.
6 minutes: obey weekly more than 10.
4, tcm symptom scoring method
Chest pain:
0 minute: do not have.
3 minutes: do not influence daily life through the alleviation of having a rest during outbreak.
6 minutes: need drug test during outbreak, can continue normal activity after the alleviation.
9 minutes: outbreak was frequent, influences activities of daily living (but as the induced symptom of wearing the clothes, take food, take a walk, defecate).
Uncomfortable in chest:
0 minute: do not have.
3 minutes: it was uncomfortable in chest to suddenly feel, but spontaneous remission.
6 minutes: outbreak uncomfortable in chest was more frequent, but did not influence live and work.
9 minutes: uncomfortable in chest continuing do not understood, and influences live and work.
Feel suffocated:
0 minute: do not have.
2 minutes: random thoughts were felt suffocated, but spontaneous remission.
4 minutes: it was heavier to feel suffocated, and can alleviate after taking medicine.
6 minutes: feel suffocated, can not thoroughly alleviate after taking medicine.
Breathe hard:
0 minute: do not have
2 minutes: breathe hard after the activity.
4 minutes: move slightly and promptly breathe hard.
6 minutes: also sense was breathed hard at ordinary times.
Two side of body distending pains:
0 minute: do not have
2 minutes: take place once in a while, but spontaneous remission.
4 minutes: whenever when excited, take place.
6 minutes: two side of body distending pains continued not understand.
Cardiopalmus:
0 minute: do not have
1 minute: accidental cardiopalmus, but spontaneous remission.
2 minutes: frequent outbreak, but can adhere to work.
3 minutes: cardiopalmus continued not understand, and influences live and work.
Picture of the tongue:
(-) is normal.
(+) dark tongue quality, or purple dark or ecchymosis, white and thin fur arranged.
Pulse condition:
(-) is normal.
(+) stringy and hesitant pulse.
5, tcm symptom state of an illness grade scale:
According to tcm symptom integration standard the state of an illness is divided into three grades:
Slightly: tcm symptom integration≤10 minute.
Moderate: tcm symptom integration 11-23 branch.
Severe: tcm symptom integration 〉=24 minute.
6, include the case standard in:
(1) meet the angina pectoris diagnosis, Chinese medical discrimination is the syndrome of qi stagnation and blood stasis experimenter.
(2) show effect the weekly experimenter of angina pectoris 〉=2 time.
(3) Electrocardioscopy has the ischemic change or the exercise test positive.
(4) age is at 18-70 between year.
(5) signature Informed Consent Form.
7, get rid of the case standard:
(1) turns out to be the coronary heart disease acute myocardial infarction on inspection, or chest pain person due to severe angina pectoris and other heart disease, severe neurosis, climacteric syndrome, the cervical spondylosis is arranged.
(2) merge the above hypertension of II level, severe pulmonary insufficiency, severe arrhythmia (rapid atrial fibrillation, room are pounced on, paroxysmal chamber speed etc.) experimenter.
(3) merge serious primary disease such as liver, kidney, hemopoietic system, psychosis experimenter.
(4) under-18s or experimenter more than 70 years old, gestation or women breast-feeding their children, allergic constitution person.
(5) participate in the experimenter of other clinical trials.
(2) physical data: 48 routine experimenters are divided into test group and matched group all from the outpatient of intracardiac section, and case situation credit is by statistics analysed, not statistically significant between group.
(3) Therapeutic Method:
Test group: 2 of the pained peaceful sheets of Moschus, take half an hour after the meal, take 4 of contrast tablet simulants simultaneously, every day 3 times.
Matched group: 4 in contrast tablet, take half an hour after the meal, take 2 of the pained peaceful sheet simulants of Moschus simultaneously, every day 3 times.
Annotate: duration of test bans use of the Chinese and western drugs of other treatment angina pectoris except that nitroglycerin.
(4) treatment conclusion:
Curative effect to treat angina pectoris:
The pained peaceful sheet test group obvious effective rate of Moschus is 47.82%, and total effective rate is 91.30%; The matched group obvious effective rate is 26.09%, and total effective rate is 73.91%.
Compare between group, P＜0.01, difference has the height statistical significance.
The tcm symptom curative effect:
The pained peaceful sheet test group total effective rate 91.30% of Moschus, matched group are to compare between 69.57%, two group, P＜0.01, and difference has the height statistical significance.
ECG curative effect: the pained peaceful sheet test group total effective rate of Moschus is 65.22%, and matched group is 47.83%, compares P＞0.05, difference not statistically significant between group.
The specific embodiment:
The Rhizoma Corydalis of 9 weight portions is added 5 times of amount 60% ethanol extractions twice, and merge extractive liquid, reclaims ethanol, and concentrate drying is made fine powder; With the Moschus of 0.1 weight portion, the Styrax of 0.3 weight portion, grind mixing altogether, just be prepared into the active ingredient of drug regimen of the present invention.Perhaps
The Rhizoma Corydalis of 20 weight portions and the Radix Ginseng Rubra of 6 weight portions are added 7 times of amount 80% ethanol extractions twice, and merge extractive liquid, reclaims ethanol, and concentrate drying is made fine powder; With the Moschus of 5 weight portions, the Styrax of 10 weight portions, grind mixing altogether, just be prepared into the active ingredient of drug regimen of the present invention.
The people of 200 weight portion Rhizoma Corydalis and 300 weight portions is participated in 9 times of amount 60% ethanol extractions twice, and merge extractive liquid, reclaims ethanol, and concentrate drying is made fine powder; With the Moschus of 40 weight portions, the Styrax of 30 weight portions, grind mixing altogether, just be prepared into the active ingredient of drug regimen of the present invention.Perhaps
Active constituent of the present invention can add different auxiliary material according to the different dosage form of preparation, binding agent if necessary, disintegrating agent, lubricant, dispersant etc. are prepared into any peroral dosage form commonly used by the Chinese medicine preparation common method, as tablet, capsule, granule, powder etc., also can utilize for formulation method, add gelatin or other excipient and make soft capsule, drop pill or other modern peroral dosage form.
The capsule preparation of medicine of the present invention:
The Rhizoma Chuanxiong of 200 weight portions, the people of 400 weight portions are participated in 9 times of amount 75% ethanol extractions twice, and merge extractive liquid, reclaims ethanol, and concentrate drying is made fine powder; The Borneolum Syntheticum of 30 weight portions is made fine powder; With the Moschus of 40 weight portions, the Styrax of 30 weight portions, grind mixing altogether, the gelatine capsule of packing into is prepared into hard capsule.
The preparation tablets of medicine of the present invention:
The Rhizoma Corydalis of 9 weight portions, the people of 6 weight portions are participated in 8 times of amount 55% ethanol extractions twice, and merge extractive liquid, reclaims ethanol, and concentrate drying is made fine powder; 0.5 the Borneolum Syntheticum of weight portion is made fine powder; With the Moschus of 0.1 weight portion, the Styrax of 0.3 weight portion, grind mixing altogether, make granule with marumerization or two step granulations, compacting is in flakes.
The tablet of making can sugar coating or film-coat.
Medicinal soft capsule preparation of the present invention:
The Rhizoma Chuanxiong of 200 weight portions, the Radix Ginseng Rubra of 400 weight portions are added 8 times of amount 70% ethanol extractions twice, and merge extractive liquid, reclaims ethanol, and concentrate drying is made fine powder; With the Moschus of 40 weight portions, the Styrax of 30 weight portions, grind mixing altogether, add gelatin or arabic gum, glycerol etc. and be pressed into soft capsule.
The drop pill preparation of medicine of the present invention:
The Rhizoma Corydalis of 9 weight portions, the Radix Ginseng Rubra of 6 weight portions are added 9 times of amount 60% ethanol extractions twice, and merge extractive liquid, reclaims ethanol, and concentrate drying is made fine powder; With the Moschus of 0.1 weight portion, the Styrax of 0.3 weight portion, grind mixing altogether, or add proper auxiliary materials and melt altogether and be mixed, drip and make drop pill.
The granule preparation of medicine of the present invention
The Rhizoma Chuanxiong of 9 weight portions, the Radix Ginseng Rubra of 6 weight portions are added 9 times of amount 70% ethanol extractions twice, and merge extractive liquid, reclaims ethanol, and concentrate drying is made fine powder; 0.5 the Borneolum Syntheticum of weight portion is made fine powder; With the Moschus of 0.1 weight portion, the Styrax of 0.3 weight portion, grind mixing altogether, in one-step-granulating method, make granule.
The pill preparation of medicine of the present invention
The Rhizoma Corydalis of 9 weight portions, the Radix Ginseng of 6 weight portions and the Rhizoma Corydalis of 9 weight portions are added 5 times of amount 65% ethanol extractions twice, and merge extractive liquid, reclaims ethanol, and concentrate drying is made fine powder; 0.5 the Borneolum Syntheticum of weight portion is made fine powder; With the Moschus of 0.1 weight portion, the Styrax of 0.3 weight portion, grind mixing altogether, make the watered pill with water pill.
Claims (4)
1, a kind of treatment treating coronary heart disease and angina pectoris is characterized in that it is the medicament made from the herbal raw material of following weight parts proportioning:
Moschus 0.1～5 Rhizoma Corydalis 9～20
Styrax 0.3～10 Radix Ginseng Rubra 6.
2, a kind of treatment treating coronary heart disease and angina pectoris according to claim 1 is characterized in that said medicament is a said oral agents on any pharmaceutics.
3, a kind of treatment treating coronary heart disease and angina pectoris according to claim 1 is characterized in that said oral agents is tablet, capsule, drop pill, watered pill, granule.
4, a kind of method for preparing the described medicine of claim 1 is characterized in that
A, the Rhizoma Corydalis of 9～20 weight portions and the red ginseng powder of 6 weight portions are broken into coarser powder, add 4～10 times of amount 40～80% ethanol, extract twice, collect extracting solution, reclaim ethanol,, make fine powder again through concentrate drying;
B, with fine powder and the Moschus of 0.1～5 weight portion, the Styrax of 0.3～10 weight portion of a operation preparation, grind mixing altogether, be processed into oral agents, encapsulate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200310105455 CN1227023C (en) | 2003-10-28 | 2003-10-28 | Drug for treating coronary heart disease, angina and preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200310105455 CN1227023C (en) | 2003-10-28 | 2003-10-28 | Drug for treating coronary heart disease, angina and preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1539474A CN1539474A (en) | 2004-10-27 |
| CN1227023C true CN1227023C (en) | 2005-11-16 |
Family
ID=34333741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200310105455 Expired - Lifetime CN1227023C (en) | 2003-10-28 | 2003-10-28 | Drug for treating coronary heart disease, angina and preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1227023C (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101084992B (en) * | 2006-06-08 | 2012-03-07 | 天津天士力制药股份有限公司 | Medicinal composition containing safflower and ginseng, preparation method and preparation |
| CN102600420A (en) * | 2012-04-01 | 2012-07-25 | 李承平 | Medicine composition for blood stasis and qi stagnation |
| CN102961451A (en) * | 2012-12-14 | 2013-03-13 | 山东宏济堂制药集团有限公司 | Traditional Chinese medicine composition used for treating coronary heart disease angina |
| CN105726901A (en) * | 2016-05-17 | 2016-07-06 | 李晓维 | Traditional Chinese medicine composition for alleviating angina pectoris |
-
2003
- 2003-10-28 CN CN 200310105455 patent/CN1227023C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1539474A (en) | 2004-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101732683A (en) | Chinese medicinal preparation for treating facial chloasma and preparation method thereof | |
| CN1915399A (en) | Preparation for treating high blood pressure, high blood fat, obesity, and climacteric syndrome, and preparation method | |
| CN101822789B (en) | Hypotensor treating essential hypertension | |
| CN1297291C (en) | Medicine for abstaining from drug addiction and its preparation | |
| CN1262299C (en) | Chinese medicine adhesive film for preventing and treating coronary heart disease and angina pectoris and its preparing method | |
| CN1726929A (en) | Compsn. of medication for treating diabetes | |
| CN1927331A (en) | Chinese medicine preparation for curing chronic heart failure | |
| CN1733242A (en) | Medicine for curing qi deficiency induced thoracic obstruction (coronary heart disease) and technique for preparing the same | |
| CN1199656C (en) | Medicine for treating myashthenia gravis | |
| CN1227023C (en) | Drug for treating coronary heart disease, angina and preparation method | |
| CN102048939B (en) | Medicament for treating sinus bradycardia | |
| CN1297290C (en) | Medicinal composition for treating coronary heart disease and stenocardia and its preparation method | |
| CN1660387A (en) | Health care preparation for regulating functional balance of organs of bowels in human body and preparing method | |
| CN1060028C (en) | Health food macte from cereal, vegetable and fruit | |
| CN1990033A (en) | Drug for treating hypertension, dense blood and arteriosclerosis | |
| CN1451422A (en) | Chinese medicine for treating fundus oculi bleeding | |
| CN105560894A (en) | Traditional Chinese medicine composition for treating allergic cheilitis and preparation method | |
| CN1232283C (en) | Chinese drugs for treatment of coronary heart disease and angina pectoris | |
| CN106474190A (en) | A kind of medicine for treating type Ⅱdiabetes mellitus and complication and preparation method thereof | |
| CN1045892C (en) | Chinese medicine Guanxintong for preventing and curing coronary heart disease and angina pectoris, and producing process thereof | |
| CN1290547C (en) | Traditional Chinese medicine for treating and preventing high blood pressure and its preparation technology | |
| CN1233361C (en) | Traditional Chinese medicine composition for treating cardiovascular disease | |
| CN1883529A (en) | A pharmaceutical composition for treating cardiovascular and cerebrovascular disease and preparation method thereof | |
| CN104324134A (en) | Traditional Chinese medicine composition for improving microcirculation and preparation method of traditional Chinese medicine composition | |
| CN1293971A (en) | Medicine for treating apoplexy and its preparing process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: SHANDONG HONGJITANG PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: HONGJITANG PHARMACY CO., LTD., JINAN |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 250100 No. 360, Hualong Road, Licheng District, Shandong, Ji'nan Patentee after: JINAN HONGJITANG PHARMACEUTICAL CO.,LTD. Address before: 250100 No. 360, Hualong Road, Licheng District, Shandong, Ji'nan Patentee before: Jinan Hongjitang Pharmaceutical Co.,Ltd. |
|
| C56 | Change in the name or address of the patentee | ||
| CP02 | Change in the address of a patent holder |
Address after: Licheng District 250103 Shandong city of Ji'nan province by ten Road No. 30766 Patentee after: JINAN HONGJITANG PHARMACEUTICAL CO.,LTD. Address before: 250100 No. 360, Hualong Road, Licheng District, Shandong, Ji'nan Patentee before: JINAN HONGJITANG PHARMACEUTICAL CO.,LTD. |
|
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 250103 No. 360, Hualong Road, Ji'nan, Shandong Patentee after: SHANDONG HONGJITANG PHARMACEUTICAL GROUP Co.,Ltd. Address before: 250103 No. 360, Hualong Road, Ji'nan, Shandong Patentee before: JINAN HONGJITANG PHARMACEUTICAL CO.,LTD. |
|
| CX01 | Expiry of patent term |
Granted publication date: 20051116 |
|
| CX01 | Expiry of patent term |